Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist available in oral tablet form. In Hong Kong it is classified as a prescription (Rx) medication and is supplied in the strengths 3 mg, 7 mg, and 14 mg. The drug is used primarily for the treatment of type 2 diabetes mellitus and, where approved, for chronic weight management in adults with obesity.
Semaglutide mimics the action of the natural incretin hormone GLP-1. After a meal, GLP-1 is released from the gut and helps regulate blood glucose by:
These effects lower post-prandial glucose spikes, reduce overall HbA1c, and can lead to modest weight loss because patients feel fuller sooner. Oral semaglutide has a bioavailability of about 1 % due to first-pass metabolism, which is why the tablet is taken on an empty stomach with only a small sip of water.
Both uses require a comprehensive care plan that includes lifestyle modification and regular monitoring.
Disclaimer: Off-label use should only occur under the direct supervision of a qualified healthcare professional after an individualized risk-benefit assessment.
Patients with these conditions should discuss alternatives with their prescriber.
These effects usually appear during dose escalation and improve over time. Taking the tablet with a small amount of water and waiting at least 30 minutes before eating or drinking other fluids can lessen gastrointestinal upset.
Patients should disclose all prescription drugs, over-the-counter products, supplements, and herbal preparations to their healthcare provider before initiating semaglutide.
Special Populations
Missed Dose - Take the missed tablet as soon as remembered if it is still the same day; otherwise, skip it and resume the regular schedule. Do not double the dose.
Overdose - Symptoms may include severe nausea, vomiting, and possible hypoglycaemia if combined with insulin or secretagogues. Seek emergency medical care; supportive measures and monitoring are the mainstays of treatment.
Discontinuation - Gradual dose reduction is not required for semaglutide, but abrupt cessation may lead to a rebound increase in blood glucose. Follow up with a clinician to assess the need for alternative therapy.
If any adverse event emerges, adjust the dose or discontinue as clinically indicated.
This article provides educational information about semaglutide and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Persisting nausea may indicate the dose is too high or that the titration schedule needs adjustment. Contact your prescriber to discuss a possible dose reduction or slower escalation. Staying hydrated and eating smaller, low-fat meals can also help alleviate symptoms.
Semaglutide can be combined with metformin and other non-insulin agents, but co-administration with insulin or sulfonylureas may increase hypoglycaemia risk. Your healthcare provider will tailor the regimen and may adjust the doses of the accompanying drugs.
Yes, provided you keep the medication in its original, sealed packaging, carry a copy of the prescription, and declare it at customs if required. Store the tablets at room temperature and avoid exposing them to extreme heat or humidity during travel.
Most patients notice a modest weight reduction within the first 12 weeks, with continued loss up to a year if the medication is maintained at the therapeutic dose and coupled with lifestyle changes. Individual results vary.
No specific foods are prohibited, but the tablet must be taken on an empty stomach. After dosing, you can eat any balanced diet; however, high-fat meals may exacerbate gastrointestinal side effects.
Weight loss associated with semaglutide often leads to modest reductions in systolic and diastolic blood pressure. Direct cardiovascular effects are minimal, but ongoing monitoring is advisable, especially in patients on antihypertensive therapy.
Both formulations contain the same active ingredient and share a similar mechanism of action. The oral form (3 mg, 7 mg, 14 mg) is taken daily on an empty stomach, while the injectable version is administered weekly. Choice depends on patient preference, absorption considerations, and prescriber recommendation.
Coverage varies by individual health plan and the specific indication. Some private insurers reimburse semaglutide for diabetes management; reimbursement for weight-loss treatment may be limited. Verify with your insurer or the Hospital Authority.
GLP-1 agonists have been associated with an increased incidence of gallbladder disease. If you have a prior history of gallstones, discuss the risk-benefit profile with your physician before starting therapy.
Keep the blister pack in a cool, dry place away from direct sunlight. If ambient temperature rises above 30 °C for an extended period, transfer the medication to a climate-controlled environment as soon as possible. Do not refrigerate the tablets.
